AR063345A1 - N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion - Google Patents

N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion

Info

Publication number
AR063345A1
AR063345A1 ARP070104641A ARP070104641A AR063345A1 AR 063345 A1 AR063345 A1 AR 063345A1 AR P070104641 A ARP070104641 A AR P070104641A AR P070104641 A ARP070104641 A AR P070104641A AR 063345 A1 AR063345 A1 AR 063345A1
Authority
AR
Argentina
Prior art keywords
methyl
quinolin
benzamide
piperidin
hydroxyethyl
Prior art date
Application number
ARP070104641A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR063345A1 publication Critical patent/AR063345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ARP070104641A 2006-10-20 2007-10-19 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion AR063345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
AR063345A1 true AR063345A1 (es) 2009-01-21

Family

ID=39314285

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104641A AR063345A1 (es) 2006-10-20 2007-10-19 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion

Country Status (32)

Country Link
US (2) US7659286B2 (https=)
EP (1) EP2079735B1 (https=)
JP (1) JP4668346B2 (https=)
KR (1) KR20090065534A (https=)
CN (1) CN101528739B (https=)
AR (1) AR063345A1 (https=)
AT (1) ATE543818T1 (https=)
AU (2) AU2007313515B2 (https=)
BR (1) BRPI0717631A2 (https=)
CA (1) CA2667041C (https=)
CL (1) CL2007003009A1 (https=)
CO (1) CO6180450A2 (https=)
CY (1) CY1112718T1 (https=)
DK (1) DK2079735T3 (https=)
ES (1) ES2379519T3 (https=)
HR (1) HRP20120344T1 (https=)
IL (1) IL197876A0 (https=)
MX (1) MX2009003974A (https=)
MY (1) MY148880A (https=)
NO (1) NO20091969L (https=)
NZ (1) NZ577060A (https=)
PE (2) PE20080892A1 (https=)
PL (1) PL2079735T3 (https=)
PT (1) PT2079735E (https=)
RS (1) RS52260B (https=)
RU (1) RU2454414C2 (https=)
SA (1) SA07280549B1 (https=)
SI (1) SI2079735T1 (https=)
TW (1) TW200826939A (https=)
UA (1) UA97648C2 (https=)
UY (1) UY30652A1 (https=)
WO (1) WO2008048171A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410347A (pt) * 2003-05-16 2006-05-30 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, métodos para as terapias da dor e de distúrbios gostrointestinais funcionais em animal de sangue quente, e, processo para preparação de um composto
MY148880A (en) * 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
EA201001644A1 (ru) * 2008-05-20 2011-06-30 Астразенека Аб Способ лечения тревожного большого депрессивного расстройства
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
EP3233825B1 (en) * 2014-12-19 2020-04-29 Pharmnovo AB Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
EP3853435B1 (en) 2018-09-21 2024-08-21 Garland Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) * 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
WO1999033806A1 (en) * 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
MXPA02006137A (es) 1999-12-20 2002-12-05 Neuromed Tech Inc Bloqueadores del canal de calcio parcialmente saturados.
EP1263758A2 (en) * 2000-03-03 2002-12-11 Ortho-McNeil Pharmaceutical, Inc. 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
BRPI0410347A (pt) * 2003-05-16 2006-05-30 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, métodos para as terapias da dor e de distúrbios gostrointestinais funcionais em animal de sangue quente, e, processo para preparação de um composto
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
DK2079735T3 (da) 2012-05-21
EP2079735A1 (en) 2009-07-22
US20080182875A1 (en) 2008-07-31
CA2667041A1 (en) 2008-04-24
KR20090065534A (ko) 2009-06-22
EP2079735B1 (en) 2012-02-01
ATE543818T1 (de) 2012-02-15
AU2007313515B2 (en) 2010-11-25
MX2009003974A (es) 2009-04-27
RS52260B (sr) 2012-10-31
CN101528739A (zh) 2009-09-09
PE20140634A1 (es) 2014-06-19
WO2008048171A1 (en) 2008-04-24
AU2007313515A1 (en) 2008-04-24
SA07280549B1 (ar) 2010-09-29
HRP20120344T1 (hr) 2012-05-31
JP4668346B2 (ja) 2011-04-13
ES2379519T3 (es) 2012-04-26
JP2010506910A (ja) 2010-03-04
PE20080892A1 (es) 2008-09-11
NZ577060A (en) 2011-01-28
BRPI0717631A2 (pt) 2013-10-29
US7659286B2 (en) 2010-02-09
PT2079735E (pt) 2012-05-07
SI2079735T1 (sl) 2012-05-31
US20100160374A1 (en) 2010-06-24
CA2667041C (en) 2011-09-06
RU2009111337A (ru) 2010-11-27
UA97648C2 (ru) 2012-03-12
IL197876A0 (en) 2009-12-24
RU2454414C2 (ru) 2012-06-27
AU2010226996A1 (en) 2010-10-28
UY30652A1 (es) 2008-05-31
HK1131556A1 (en) 2010-01-29
NO20091969L (no) 2009-05-20
EP2079735A4 (en) 2010-12-29
MY148880A (en) 2013-06-14
CY1112718T1 (el) 2016-02-10
CN101528739B (zh) 2011-11-30
CL2007003009A1 (es) 2008-06-06
TW200826939A (en) 2008-07-01
CO6180450A2 (es) 2010-07-19
PL2079735T3 (pl) 2012-07-31
US7977355B2 (en) 2011-07-12

Similar Documents

Publication Publication Date Title
PE20211478A1 (es) Formas cristalinas novedosas
AR063345A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion
CL2008002162A1 (es) Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.
ECSP099476A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
CL2008002622A1 (es) 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno.
UY30779A1 (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2015001557A1 (es) Compuestos derivados e n-(3-{[4-(alquil/cicloalquil-carbonil)piperazin-1-il]metil}fenil)formamida, moduladores del receptor gamma huérfano relacionado con retinoide (ror-gamma); composicion farmaceutica; y su uso en el tratamiento de esclerosis multiple y/o psoriasis.
CU20090058A7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
NO20083246L (no) Nye benzimidazolderivater som vanilloid-reseptor 1 (VRL) inhibitorer
ECSP11011503A (es) Compuestos carboxamida y su uso como inhibidores de calpaína.
NO20072005L (no) Nye heterocykliske amider
MX2019002615A (es) Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.
AR053169A1 (es) Metabolitos de n-2 (cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil) -2-metil -4-pi rimidinil] amino]-5-tiazol carboxamidas
CL2007003396A1 (es) Uso de agomelatina o n-[2-(7-metoxi-1-naftil)etil]acetamida para el tratamiento del sindrome de smith magenis; composicion farmaceutica que contiene agomelatina.
NO20080661L (no) Nye cystein-protease-inhibitorer og deres terapeutiske anvendelser
CL2007003043A1 (es) Compuestos derivados de cromano; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y ansiedad entre otros.
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
CL2004000730A1 (es) Compuestos derivados de 4-[2-(fenilsulfanil sustituido)fenil]-1,2,3,6-tetrahidropiridina; composicion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansiedad so
CR9426A (es) Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares
CL2008002688A1 (es) Formas polimorficas de (s)-2((4-benzofuranil)carbonilaminometil)-1-((4-(2-metil-5-(4-fluorofenil))tiazolil)carbonil)piperidina; composicion farmaceutica; y uso para el tratamiento o profilaxis de trastornos del sueño, depresion, ansiedad, trastornos relacionados con sustancias y trastornos relacionados con sustancias y trastornos alimentarios.
CL2007003426A1 (es) Compuestos derivados de dialquilaminoalquilo de pigavabina; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos afectivos, depresivos, de ansiedad.
CL2008003047A1 (es) Compuestos derivados de n-(2- fluoro-3-alquiloxifenil)metilquinolina-6- carboxamida; agente controlador de enfermedades de las plantas que contiene a dichos compuestos; metodo para controlar enfermedades de las plantas; uso de dichos compuestos; y compuestos intermediarios.
GT200000114A (es) Forma cristalina iii de la n-(4-(5-dimetilaminoftalen-1-sulfonilamino) fenil)-3-hidroxi-2, 2-dimetilpropionamida.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal